Iterion Therapeutics

10/08/2022

Iterion is proud to continue sponsoring National Pediatric Cancer Foundation.

12/09/2021

We are Initiating a Phase 1 clinical trial to investigate tegavivint in a first-line combination study with osimertinib in previously untreated patients with metastatic epidermal growth factor receptor (EGFR)-positive Non-Small Cell Lung Cancer (NSCLC).

/PRNewswire/ -- Iterion Therapeutics, Inc., a venture-backed, clinical-stage biotechnology company developing novel cancer therapeutics, today announced the...

11/09/2021

Initiation of Phase 1/2 Clinical Trial to Study Tegavivint in Pediatric Cancers

/PRNewswire/ -- Iterion Therapeutics, Inc., a venture-backed, clinical-stage biotechnology company developing novel cancer therapeutics, today announced the...

10/19/2021

Great things happening as we continue our research.

/PRNewswire/ -- Iterion Therapeutics, Inc., a venture-backed, clinical-stage biotechnology company developing novel cancer therapeutics, today announced the...

09/29/2021

Iterion is a proud sponsor of National Pediatric Cancer Foundation. We are excited to be part of this years Houston event - Fashion Funds the Cure! If you would like more information please see National Pediatric Cancer Foundation

07/14/2021

Join us in our excitment as we welcome our new Chief Operating Officer, Jean Chang.

/PRNewswire/ -- Iterion Therapeutics, Inc., a venture-backed, clinical-stage biotechnology company developing novel cancer therapeutics, today announced the...

04/13/2021

Exciting times for us!

/PRNewswire/ -- Iterion Therapeutics, Inc., a venture-backed, clinical stage biotechnology company developing novel cancer therapeutics, announced today that...

03/30/2021

Our very own Director of Translation Research
Ruolan Han, PhD

Ruolan Han, PhD, explains how targeting TBL1/TBLR1 enables specific silencing of oncogenic Wnt target gene expression without affecting other necessary cellular functions that are disrupted when targeting higher up the Wnt pathway.

02/10/2021

We are excited to announce that we have entered into a strategic collaboration with Apollomics, the ideal partner to advance Tegavivint in the Greater China region.

https://www.globenewswire.com/news-release/2021/02/10/2173075/0/en/Apollomics-Inc-and-Iterion-Therapeutics-Announce-Exclusive-Collaboration-and-License-Agreement-to-Develop-and-Commercialize-Tegavivint-in-Greater-China.html

07/28/2020

http://www.prnewswire.com/news-releases/iterion-therapeutics-initiates-enrollment-of-phase-2a-dose-expansion-study-of-tegavivint-in-patients-with-desmoid-tumors-301100338.html?tc=eml_cleartime

/PRNewswire/ -- Iterion Therapeutics, Inc., a venture-backed, clinical stage biotechnology company developing novel cancer therapeutics, announced today that...

12/05/2018

https://www.businesswire.com/news/home/20181205005630/en/Iterion-Therapeutics-Initiates-Phase-Clinical-Study-Tegavivint

Iterion Therapeutics, formerly known as Beta Cat Pharmaceuticals, today announced that it has initiated a multi-center Phase I clinical study of Tegav